Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Thioridazine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.98 |
| ▸ | DRD3 known ✓ | P35462 | 4/20 | 0.98 |
| ▸ | HTR2A known ✓ | P28223 | 4/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 1/20 | 0.98 |
| ▸ | HTR2C known ✓ | P28335 | 1/20 | 0.98 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | TP53 | P04637 | 2/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 2/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 2/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | GMNN | O75496 | 1/20 | 1.00 |
| ▸ | LMNA | P02545 | 1/20 | 1.00 |
| ▸ | STAT6 | P42226 | 1/20 | 1.00 |
| ▸ | RAD52 | P43351 | 1/20 | 1.00 |
| ▸ | PMP22 | Q01453 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Thioridazine SCHEMBL30827481 | 1.00 | TDP1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL8006297 | 1.00 | TDP1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL29387384 | 1.00 | TDP1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL380206 | 0.99 | PIM1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL9566 | 0.99 | PIM1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL29384252 | 0.99 | PIM1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL2577719 | 0.99 | PIM1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL12434241 | 0.99 | PIM1 (1.00) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL56533 | 0.97 | PIM1 (0.96) | TDP1MAPTALDH1A1TP53CYP3A4 | |
| Thioridazine SCHEMBL2321422 | 0.93 | TDP1 (0.87) | TDP1MAPTALDH1A1TP53CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 8758 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-120053460-A | Pharmaceutical composition for preventing or treating flavivirus infection | 雷莫内克斯生物制药有限公司 | 2025-05-30 | — | — | CN | claimed |
| US-12295967-B2 | Pharmaceutical composition for prevention or treatment of flavivirus infection | LEMONEX INC. (KR) | 2025-05-13 | — | — | US | claimed |
| CN-117929597-A | Method for simultaneously detecting content of six sedatives in feed | 广东省农业科学院农业质量标准与监测技术研究所 | 2024-04-26 | — | — | CN | claimed |
| EP-3785718-B1 | PHARMACEUTICAL COMPOSITION FOR PREVENTION OR TREATMENT OF FLAVIVIRUS INFECTIOUS DISEASE | LEMONEX INC (KR) | 2024-03-27 | — | — | EP | claimed |
| US-20230221321-A1 | METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER | UNIVERSITÉ PARIS-SACLAY (FR) | 2023-07-13 | — | — | US | claimed |
| EP-4111200-A1 | METHOD FOR IDENTIFYING COMPOUNDS USEFUL FOR THE TREATMENT OF CANCER | Université Paris-Saclay (FR) | 2023-01-04 | — | — | EP | claimed |
| CN-112999230-B | Application of cryptotanshinone in preparation of bacterial respiratory chain inhibitor | 浙江中医药大学 | 2022-08-02 | — | — | CN | claimed |
| EP-3994202-A1 | NOVEL HYDROGELS | Leibniz-Institut für Neue Materialien gemeinnützige GmbH (DE) | 2022-05-11 | — | — | EP | claimed |
| US-20220050117-A1 | GLX-DERIVED MOLECULE DETECTION | GLX ANALYTIX APS (DK) | 2022-02-17 | — | — | US | claimed |
| CN-113209050-A | Long-acting in vivo skin-embedded or implanted sustained-release preparation based on biocompatible polymer | 浙江恒冀制药有限责任公司 | 2021-08-06 | — | — | CN | claimed |
| US-5563014-A | SOFTENABLE LAYER CONTAINIG PHOTOSENSITIVE MARKING MATERIAL; TRANSPARENTIZING AGENT | XEROX CORPORATION (US) | 1996-10-08 | — | — | US | claimed |
| US-5514505-A | SELECTIVE TRANSPARENTIZATION OF PHOTOSENSITIVE MIGRATION MARKING PARTICLES EMBEDDED NEAR THE SURFACE OF A SOFTENABLE LAYER SUPPORTED BY AN ELECTROCONDUCTIVE SUBSTRATE | XEROX CORPORATION (US) | 1996-05-07 | — | — | US | claimed |
| EP-0681210-A1 | Novel developing agents for (photo) thermographic systems | MINNESOTA MINING AND MANUFACTURING COMPANY (US) | 1995-11-08 | — | — | EP | claimed |
| EP-0500650-B1 | PROCESS FOR PRODUCING A GEL-FREE COAGULATED RUBBER WITH LOW ETHYLENIC UNSATURATION | OLIN CORP (US) | 1995-08-09 | — | — | EP | claimed |
| EP-0580776-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1994-02-02 | — | — | EP | claimed |
| EP-0500650-A4 | PROCESS FOR PRODUCING A GEL-FREE COAGULATED RUBBER WITH LOW ETHYLENIC UNSATURATION | — | 1992-11-25 | — | — | EP | claimed |
| WO-1992018127-A1 | USE OF SIGMA RECEPTOR ANTAGONISTS TO ENHANCE THE EFFECTS OF ANTIPSYCHOTIC DRUGS | THE DU PONT MERCK PHARMACEUTICAL COMPANY (US) | 1992-10-29 | — | — | WO | claimed |
| EP-0500650-A1 | PROCESS FOR PRODUCING A GEL-FREE COAGULATED RUBBER WITH LOW ETHYLENIC UNSATURATION. | OLIN CORP (US) | 1992-09-02 | — | — | EP | claimed |
| US-5057601-A | PROCESS FOR PRODUCING A GEL-FREE COAGULATED RUBBER WITH LOW ETHYLENIC UNSATURATION | OLIN CORPORATION (US) | 1991-10-15 | — | — | US | claimed |
| WO-1991006579-A1 | PROCESS FOR PRODUCING A GEL-FREE COAGULATED RUBBER WITH LOW ETHYLENIC UNSATURATION | OLIN CORPORATION (US) | 1991-05-16 | — | — | WO | claimed |